🔗 Share this article

As the US proceeds with unprecedented revisions to its immunization schedules, an unexpected name appears somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus vaccines in the global health crisis and has focused upon possible deaths after COVID-19 immunization in her short tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Schedule

Health officials planned to unveil radical changes to the pediatric immunization program in December, aligning the US with the Danish national calendar, according to reports – a significant shift that would place the US out of alignment with a large portion of the world with insufficient data for public health gain. The planned update has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth person to head the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics centers as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for discontinuing specific pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a country with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Expertise

Dr. Høeg has no obvious experience in pharmaceutical research, approval processes or management, which has been typical for previous heads of the CBER. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former directors of the center would “be deeply familiar with legal statutes and the science of medication creation”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who headed the center have had.”

This division has an enormous range of responsibilities at the agency, Woodcock emphasized.

“Everybody just focuses on the novel medication approvals, but the generic program clears thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and other areas, and every single one must be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial management aspect to the job, which oversees more than 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” she added.

Official Statement and Controversial Initiatives

Regarding concerns about Dr. Høeg's qualifications and whether this selection signifies increased cooperation among FDA leaders on immunizations, a spokesperson responded that the “questions rely on inaccurate presumptions”.

“This background aligns with the functions of her role,” the representative explained, citing the time Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's recently launched fast-track approval initiative, a contentious rapid drug-approval program that apparently troubled her predecessors. “How are these drugs being chosen for this expedited pathway? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards laxer oversight of all drugs, with the exception of shots.”

Public History on Vaccines

Regarding vaccines, Høeg has a more established, if problematic, track record, Howard observe. She authored a study using non-validated public submissions to determine the frequency of myocarditis following Covid immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the current administration encompassed changing regulations for new vaccines and ending “non-essential” immunizations, she said following the vote on a audio program. At the agency, Høeg has reportedly suggested excluding adolescent males from obtaining COVID-19 vaccinations.

“She is an complete ideologue who begins with her conclusions and tailors the evidence to fit the science in a highly disingenuous, dishonest fashion,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|